Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53

Abstract

Many oncolytic viruses are currently being tested as potential cancer therapeutic agents. To be effective, these viruses must replicate and propagate efficiently through the tumor mass. However, it is possible that the hypoxia that characterizes many tumors may be an obstacle to viral therapy because of its inhibition of viral replication and propagation. We, therefore, decided to test how oncolytic reovirus and its target cells respond to hypoxia. We found that reovirus infection suppresses hypoxia inducible factor (HIF)-1α protein levels (but not transcript abundance) in colon cancer HCT116 cells under CoCl2 or hypoxia. Reovirus infection was able to reduce HIF-1α levels in both von Hippel Lindau (VHL)−/− renal carcinoma A498 and p53−/− HCT116 cells, indicating that the decrease of HIF-1α mediated by reovirus requires neither VHL nor p53 proteins. However, treatment with the inhibitor MG132 restored HIF-1α levels, suggesting that reovirus-induced HIF-1α decrease needs proteosomal activity. A498 VHL−/− cells with constitutive expression of HIF-1α were relatively resistant to reovirus-induced apoptosis when compared with A498 VHL+/+ cells. However, we found that the use of YC-1 to target HIF-1α promoted reovirus-induced apoptosis in A498 VHL−/− cells. Accordingly, we propose that reovirus may be used together with YC-1 as a potential therapeutic agent against chemoresistant or radioresistant tumors that are hypoxic and show increased levels of HIF-1α.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Hockel M, Vaupel P . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266–276.

    Article  CAS  Google Scholar 

  2. Brown JM, Wilson WR . Exploiting tumour hypoxia in cancer treatment. Nat Rev 2004; 4: 437–447.

    Article  CAS  Google Scholar 

  3. Bardos JI, Ashcroft M . Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262–269.

    Article  CAS  Google Scholar 

  4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (New York, NY) 2001; 292: 468–472.

    Article  CAS  Google Scholar 

  5. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–275.

    Article  CAS  Google Scholar 

  6. Tanimoto K, Makino Y, Pereira T, Poellinger L . Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298–4309.

    Article  CAS  Google Scholar 

  7. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW . Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad SciUSAm 2004; 101: 11099–11104.

    Article  CAS  Google Scholar 

  8. Kim M, Chung YH, Johnston RN . Reovirus and tumor oncolysis. J Microbiol (Seoul, Korea) 2007; 45: 187–192.

    CAS  Google Scholar 

  9. Rosen L, Evans HE, Spickard A . Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37.

    CAS  PubMed  Google Scholar 

  10. Nibert ML, Schiff LA, Fields BN . Mammalian reoviruses contain a myristoylated structural protein. J Virol 1991; 65: 1960–1967.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science (New York, NY) 1998; 282: 1332–1334.

    Article  CAS  Google Scholar 

  12. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–353.

    CAS  Google Scholar 

  13. Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH et al. Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther 2009; 16: 453–461.

    Article  CAS  Google Scholar 

  14. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576.

    Article  Google Scholar 

  15. Ring CJ . Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83 (Part 3): 491–502.

    Article  Google Scholar 

  16. Russel FG, Masereeuw R, van Aubel RA . Molecular aspects of renal anionic drug transport. Ann Rev Physiol 2002; 64: 563–594.

    Article  CAS  Google Scholar 

  17. Norman KL, Lee PW . Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847–855.

    Article  CAS  Google Scholar 

  18. Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M . Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris, Nasus, Larynx 2004; 31: 407–412.

    Article  Google Scholar 

  19. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ . Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003; 39: 414–420.

    Article  CAS  Google Scholar 

  20. Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL . Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 2001; 20: 6910–6919.

    Article  CAS  Google Scholar 

  21. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC . YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320: 161–166.

    Article  CAS  Google Scholar 

  22. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61: 947–954.

    Article  CAS  Google Scholar 

  23. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516–525.

    Article  CAS  Google Scholar 

  24. Giaccia A, Siim BG, Johnson RS . HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803–811.

    Article  CAS  Google Scholar 

  25. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y et al. Reovirus therapy of lymphoid malignancies. Blood 2002; 100: 4146–4153.

    Article  CAS  Google Scholar 

  26. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J . Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019–2028.

    Article  CAS  Google Scholar 

  27. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772–5781.

    Article  CAS  Google Scholar 

  28. Levine AJ . p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.

    Article  CAS  Google Scholar 

  29. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD . p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395–405.

    Article  CAS  Google Scholar 

  30. Kim HY, Kim YH, Nam BH, Kong HJ, Kim HH, Kim YJ et al. HIF-1alpha expression in response to lipopolysaccaride mediates induction of hepatic inflammatory cytokine TNFalpha. Exp Cell Res 2007; 313: 1866–1876.

    Article  CAS  Google Scholar 

  31. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076–39084.

    Article  CAS  Google Scholar 

  32. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS . Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004; 24: 5223–5234.

    Article  CAS  Google Scholar 

  33. Cheng J, Kang X, Zhang S, Yeh ET . SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007; 131: 584–595.

    Article  CAS  Google Scholar 

  34. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL . RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007; 25: 207–217.

    Article  Google Scholar 

  35. Hwang II, Watson IR, Der SD, Ohh M . Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 2006; 80: 10712–10723.

    Article  CAS  Google Scholar 

  36. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F et al. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006; 66: 1684–1936.

    Article  CAS  Google Scholar 

  37. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946–956.

    Article  CAS  Google Scholar 

  38. Escuin D, Kline ER, Giannakakou P . Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65: 9021–9028.

    Article  CAS  Google Scholar 

  39. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G . The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2: 235–243.

    CAS  PubMed  Google Scholar 

  40. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007; 26: 3941–3951.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST) (2009-0071348) and by grant no. R31-2008-000-20004-0 from WCU project of the MEST and the KOSEF (YHC). This work was also supported by the Research Program for New Drug Target Discovery (M10748000195-08N4800-19510) grant from the Ministry of Education, Science and Technology to SSK.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Y-H Chung.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cho, IR., Koh, S., Min, HJ. et al. Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther 17, 365–372 (2010). https://doi.org/10.1038/cgt.2009.84

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2009.84

Keywords

This article is cited by

Search

Quick links